Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Genexys BioMed
Cincinnati, Ohio, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Genexys BioMed is advancing a non-viral, non-lipid gene therapy platform (GeneZip) for cystic fibrosis. Their lead candidate (GEN-023) aims to restore CFTR function using a mutation-agnostic approach that bypasses viral and lipid-based vector limitations. Supported by a $320K NIH/NHLBI SBIR grant, the platform has shown promising in vitro and in vivo results, but has not yet entered clinical trials[4][5][6].
- Therapeutic areas
- Rare DiseasesPulmonology
- Modalities
- Gene therapyDNA nanoparticlePolymer-based gene delivery
- Industry
- Biotech
02
Partnerships
Cincinnati Children's Hospital Medical Center
Beyond the preview
Go deeper on Genexys BioMed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genexys BioMed.